Malvern Panalytical & Leukocare collaborate on stabilization and formulation development of COVID-19 vaccines

Malvern Panalytical and Leukocare have announced an exciting collaboration aiming to improve the availability of vaccines for COVID-19. They will combine Leukocare’s pioneering expertise in biopharmaceutical formulation development with Malvern Panalytical’s extensive analytical know-how to understand how the stability of vaccines can be improved, increasing production and simplifying distribution.

Dr. Andreas Seidl, Chief Operating Officer at Leukocare, commented, “I am excited and thankful to start this collaboration in these unprecedented times. While we have already seen tremendous efforts and several successes on approvals of vaccines targeting the COVID-19 pandemic in the past few months, there still is a high unmet need for improved stability, supply and storage conditions to serve the vast majority of people and countries over the upcoming months and years. Our collaboration with Malvern Panalytical will help us to work even better on our ongoing and future projects to achieve stability improvements for a range of vaccines.”

Mark Fleiner, President of Malvern Panalytical, also expressed excitement about the opportunities presented by this project. “We have all experienced the impact of the current COVID-19 pandemic on the lives of our families, friends, and work colleagues” stated Mark. “The availability of vaccines brings hope to us all – so we jumped at the opportunity to be involved in this deep collaboration with Leukocare working together to understand how vaccine stability can be improved and ensure wider availability.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>